Clinical efficacy of cefoperazone in obstetric and gynecologic infections.
Compared with second-generation cephalosporins, cefoperazone, a third-generation cephalosporin, has demonstrated an extended antibacterial spectrum. In addition, it has a long serum half-life and requires only twice-a-day administration. In this study, 66 patients with clinically diagnosed obstetric and gynecologic infections were treated with cefoperazone, and 61 were evaluated for efficacy. An overall cure rate of 93% (57 patients) was achieved. In view of the excellent clinical response and convenience of twice-a-day administration, we conclude that cefoperazone is a clinically useful single agent for the initial empirical treatment of patients with obstetric and gynecologic infections.
D000031:Abortion, Septic / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004716:Endometritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D010460:Peptococcus; D010462:Peptostreptococcus; D011183:Postoperative Complications / Q000188:drug therapy; D011247:Pregnancy; D013290:Streptococcal Infections / Q000188:drug therapy; D013292:Streptococcus agalactiae
D002438:Cefoperazone